StockNews.com assumed coverage on shares of AbbVie (NYSE:ABBV – Get Rating) in a research report sent to investors on Thursday. The brokerage issued a strong-buy rating on the stock. A number of other analysts also recently commented on ABBV. Piper Jaffray Companies upped their price objective on AbbVie from $157.00 to $163.00 and gave the […]
Argent Trust Co lessened its stake in AbbVie Inc. (NYSE:ABBV – Get Rating) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 179,778 shares of the company’s stock after selling 864 shares during the quarter. AbbVie comprises approximately 1.9% […]
Tekla Capital Management LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV – Get Rating) by 9.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 478,342 shares of the company’s stock after selling 48,500 shares during the quarter. AbbVie comprises approximately 2.9% of Tekla Capital […]
Asahi Life Asset Management CO. LTD. lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 4.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 6,125 shares of the company’s stock after selling 270 shares during the period. Asahi Life Asset Management CO. LTD.’s holdings in AbbVie were worth $990,000 […]
Argent Trust Co lessened its stake in AbbVie Inc. (NYSE:ABBV – Get Rating) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 179,778 shares of the company’s stock after selling 864 shares during the quarter. AbbVie comprises approximately 1.9% […]